Mazdutide
Also known as: IBI362, LY3305677
Dual GLP-1/Glucagon Receptor Agonist | Weight Loss & Diabetes
Overview
First-in-class dual GLP-1 and glucagon receptor agonist combining appetite suppression with thermogenesis stimulation. Phase 3 trials demonstrated superiority over semaglutide for weight loss and glycemic control.
Key benefits
- Up to 20% body weight loss
- Superior glycemic control versus semaglutide
- Increased energy expenditure via glucagon receptor activation
- Improved cardiometabolic markers (BP, lipids, liver fat)
- Once-weekly injection convenience
Mechanism of action
Dual agonist activation: GLP-1 stimulates insulin, suppresses glucagon, slows gastric emptying; Glucagon increases energy expenditure and thermogenesis while GLP-1 counteracts glucose-raising effects.
Molecular data
- Type
- Oxyntomodulin analog with fatty acid conjugation
- Half-life
- 6-8 days
Sequence
33-amino acid linear synthetic peptide
Indications
What the research community uses this compound for, with self-reported effectiveness.
Weight Loss
Severe Obesity Management
Most effectiveGLORY-2 demonstrated 20.1% weight loss with 9mg over 60 weeks; 48.7% achieved ≥20% reduction.
Metabolic Syndrome Improvement
Most effectiveSignificant reductions in waist circumference, systolic BP (-7.57 mmHg), triglycerides (-43%).
Liver Fat Reduction
Most effectiveExploratory analysis showed 80.2% reduction in liver fat, suggesting MASLD/MASH benefits.
Type 2 Diabetes
Glycemic Control
Most effectiveHbA1c reductions of 1.41-2.03% across trials; DREAMS-3 showed -2.03% vs semaglutide -1.84%.
Dual Endpoint Achievement
Most effective48% achieved HbA1c <7.0% AND ≥10% weight loss versus 21% with semaglutide.
Cardiovascular
Blood Pressure Reduction
EffectiveSystolic reduction of -7.57 mmHg, diastolic -2.98 mmHg in clinical trials.
Lipid Profile Enhancement
EffectiveTotal cholesterol -16.82%, triglycerides -43.29%, LDL -17.07%.
Dosing protocols
Common protocols by delivery method. Adjust the curve below to model accumulation in your own cycle.
Injectable
Subcutaneous injection delivering dual GLP-1/glucagon agonism with once-weekly dosing enabled by fatty acid conjugation.
| Protocol | Dose | Frequency | Route / duration |
|---|---|---|---|
| Weight loss initiation (3mg target) | 1.5mg → 3mg | Once weekly | SubQ |
| Weight loss progression (4.5mg target) | 1.5mg → 3mg → 4.5mg | Once weekly | SubQ |
| Weight loss optimization (6mg target) | 2mg → 4mg → 6mg | Once weekly | SubQ |
| Maximum weight loss (9mg target) | 3mg → 6mg → 9mg | Once weekly | SubQ |
| T2D management (mild-moderate) | 3-4.5mg weekly | Once weekly | SubQ |
Preparation
You will need
- Mazdutide lyophilized powder vial
- Bacteriostatic water (BAC) for injection
- Insulin syringes (29-31 gauge)
- Alcohol prep pads
- Refrigerator (2-8°C)
Steps
- Allow vial to reach room temperature (15-20 minutes)
- Clean vial top with alcohol swab, air dry completely
- Calculate reconstitution volume for desired concentration
- Draw bacteriostatic water into syringe, remove air bubbles
- Inject BAC water slowly down vial side—drop by drop to prevent foaming
- Gently swirl vial in circular motion
- Verify complete clarity and colorless appearance
- Label vial with reconstitution date and concentration
- Store at 2-8°C, use within 30 days
Work out the water volume and syringe units in the reconstitution calculator →
Interactions
Pairwise interactions with other compounds you might be cycling — the same data behind the cycle builder's safety check.
Semaglutide
AvoidBoth are GLP-1 agonists; combining increases hypoglycemia and severe GI side effect risk.
Tirzepatide
AvoidBoth target GLP-1 receptor; additive effects on GI symptoms and hypoglycemia risk.
Liraglutide
AvoidAnother GLP-1 agonist; dual therapy contraindicated due to additive receptor activation.
Insulin
MonitorMay require significant dose reduction due to improved glucose control; monitor for hypoglycemia.
Sulfonylureas
MonitorIncreased hypoglycemia risk; dose reduction may be necessary.
Oral Contraceptives
MonitorDelayed gastric emptying may affect absorption; separate administration by 1 hour.
Metformin
SynergisticComplementary mechanisms; clinical trials allowed stable metformin use with enhanced efficacy.
BPC-157
CompatibleNo known interactions; may support gut health and potentially reduce GI side effects.
Timeline
Typical week-by-week effects reported in clinical and observational data.
- Week 1-2
Appetite reduction, possible mild nausea, decreased portion sizes
- Week 3-4
Early weight loss begins (1-2%), improved satiety after meals
- Week 4-8
Dose escalation phase, GI symptoms typically improving, 3-5% weight loss
- Week 8-16
Steady weight loss continues (7-12%), energy expenditure effects evident
- Week 16-32
Significant weight reduction (12-17%), metabolic markers improving
- Week 32-60
Peak effects (up to 20% weight loss), sustained improvements in BP, lipids, glucose
Safety
Reported adverse effects, contraindications, and what to monitor on cycle.
Common side effects
- Nausea (mild-moderate, typically improves over time)
- Diarrhea
- Vomiting
- Increased heart rate (5-17 bpm observed)
Stop signs — stop and seek advice
- Severe or persistent abdominal pain (potential pancreatitis)
- Neck lumps, hoarseness, or difficulty swallowing
- Severe nausea/vomiting preventing adequate nutrition or hydration
- Signs of severe hypoglycemia (confusion, sweating, shakiness)
- Severe allergic reactions (rash, difficulty breathing, facial swelling)
- Unusual mood changes, depression, or suicidal thoughts
- Signs of gallbladder problems (severe upper right abdominal pain)
Contraindications
- Personal or family history of medullary thyroid carcinoma
- MEN2 syndrome history (class warning for GLP-1 agonists)
- Pregnancy or breastfeeding (insufficient safety data)
Monitoring
- Start with lowest dose, escalate gradually every 4 weeks
- Monitor blood glucose if taking insulin or sulfonylureas
- Watch for pancreatitis symptoms
- Monitor thyroid function
- Maintain adequate hydration during initial weeks
Quality checks
What a legitimate product looks like, what should give pause, and what should make you stop.
Good signs
- White to off-white lyophilized powder without clumping or discoloration
- Completely clear and colorless appearance after reconstitution—no visible particles
- Intact vial seal and clear labeling with mg dosage, batch numbers, expiration dates
Warning signs
- Source verification critical—available from research chemical suppliers
Stop signs — don't use
- Clumping, discoloration, or moisture in powder
- Persistent cloudiness or particles after reconstitution indicates degradation
References
Primary literature and clinical-trial data informing this entry.
GLORY-1 Phase 3 Trial
2025
610 Chinese adults with obesity/overweight; 48 weeks. First Phase 3 weight management trial showing clinically meaningful weight reductions. NEJM.
GLORY-2 Phase 3 Trial
2025
462 Chinese adults with obesity; 60 weeks; 9mg dose. 20.1% weight loss vs 2.8% placebo; 48.7% achieved ≥20% reduction; no plateau observed.
DREAMS-3 Phase 3 Trial - Head-to-Head vs Semaglutide
2025
349 Chinese adults with T2D and obesity; 32 weeks. Mazdutide superiority: 48% vs 21% achieved HbA1c <7.0% AND ≥10% weight reduction (p<0.0001).
Phase 2 T2D Trial
2024
Chinese adults with T2D; 20 weeks. HbA1c reductions 1.41-1.67% vs 0.03% placebo; weight loss up to 7.1%. Diabetes Care.
Last updated . How this page was sourced is described in the methodology.